Navigation Links
First European Patient Treated in CABERNET Trial With Novel Treatment for Wet AMD
Date:11/29/2007

Ophthalmic Clinic in Germany First in Europe To Treat Patients With New

Focused Radiation Therapy

LEIPZIG, Germany, November 29 /PRNewswire/ -- NeoVista, Inc. announced today that the first European patient has been treated in the company's pivotal global clinical trial for its novel beta radiation epiretinal therapy for the wet form of age-related macular degeneration (AMD). Wet AMD is the most progressive form of AMD and one of the leading causes of blindness in the industrialized world for patients over 50. Unlike the current standard of care which requires costly monthly eye injections, NeoVista's investigational therapy delivers a one-time dose of radiation providing a less invasive and potentially more cost-effective treatment option.

The procedure was performed as part of NeoVista's CABERNET (CNV Secondary to AMD Treated with BEta RaditioN Epiretinal Therapy) trial, which seeks to enroll a total of 450 patients (300 in the radiation treatment arm) in approximately 40 sites worldwide to evaluate the efficacy and safety of NeoVista's novel radiation therapy. Patients in the study receive a single treatment with NeoVista's targeted radiation in combination with an injection of Lucentis(R) at the time of radiation delivery to maximize immediate effect.

"We're excited to have the opportunity to try this innovative technique with our patients. NeoVista's targeted radiation treatment may provide us the ability to improve vision for the elderly and dramatically change their quality of life by eliminating frequent eye injections," said Christian Foja, MD Leipzig University Eye Hospital, who performed the procedure.

Peter Wiedemann, MD, who oversees the department at Leipzig University Eye Hospital, echoed Dr. Foja's sentiments. "NeoVista is developing a promising new wet AMD treatment that could also be a cost-effective alternative in Europe," said Dr. Wiedemann. "And without having to perform regular, monthl
'/>"/>

SOURCE NeoVista, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
3. Kewaunee Scientific Announces First Quarter Results and Quarterly Dividend
4. Genmab Announces 2007 First Half Year Results
5. Pharsight Achieves First License Sale for Public-Source Database
6. Novare Announces First Ever Single Port Laparoscopic Kidney Removal (Nephrectomy) Using RealHand(TM) HD Instruments
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. China Medical Technologies Reports First Quarter Financial Results
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
11. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... led by George Washington University Professor Tianshu Li ... in small droplets is strongly size-dependent, an important ... The formation of ice at the nanoscale is ... also has important implications for climate research and ... from supercooled water is generally initiated by a ...
(Date:5/21/2013)... Smarter Security, Inc., provider of premium, innovative ... Genzyme, a Sanofi company and leading biotech company, recently ... a multi-use facility in the United States. With Door ... this latest order underscores the satisfaction and success the ... device improving doorway access control. , “We recommend ...
(Date:5/21/2013)... May 21, 2013  MacroGenics, Inc. today announced ... margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody (MAb), ... HER2 oncoprotein," will be presented at the 2013 ... Oncology during the Developmental Therapeutics - Immunotherapy Oral ... – 4:30 PM.  The presentation will describe the ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 NANONEX ... nanoimprint solutions , today announced the successful delivery ... manufacturing system, the NX-M200B, to a major Japanese ... is a fully-automated, production-ready, advanced nanoimprint lithography tool ... of wafer and substrate sizes and types. Based ...
Breaking Biology Technology:Study led by GW professor provides better understanding of water's freezing behavior at nanoscale 2Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security 2Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security 3MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3Nanonex Announces the Shipment and Installation of an Innovative Nanoimprint Lithography System for Fully Automated Manufacturing 2
... GOTHENBURG, Sweden, July 22 Cellectricon, a leading,provider of ... its collaboration with University of Lodz, Poland. Under the,agreement ... for high throughput transfection enabling reagent-free delivery of any,genetic ... view the Multimedia News Release, please click: , ...
... , , MADISON, Wis., July ... today the appointment of Junying Yu , Ph.D., ... shown her to be one of the leading stem cell researchers ... accelerate the company,s efforts toward harnessing the power of induced pluripotent ...
... , , SALT LAKE ... spine care through the development of molecular diagnostics, and the ... a collaboration that allows Axial access to the University,s rich ... a genealogical and family history database composed of more than ...
Cached Biology Technology:University of Lodz Invests in the Unique Cellaxess(R)HT System for Research on Multidrug Resistance Genes in Cancer 2Junying Yu, Leading Stem Cell Researcher, Joins Cellular Dynamics International 2Junying Yu, Leading Stem Cell Researcher, Joins Cellular Dynamics International 3Junying Yu, Leading Stem Cell Researcher, Joins Cellular Dynamics International 4Axial Biotech Enters Partnership with the University of Utah to Utilize the Utah Population Database to Develop Personalized Diagnostic Tests for Spine Disorders 2Axial Biotech Enters Partnership with the University of Utah to Utilize the Utah Population Database to Develop Personalized Diagnostic Tests for Spine Disorders 3
(Date:5/21/2013)... Widely available in pharmacies and health stores, phosphatidylserine ... oysters, and soy. Proven to improve cognition and ... older people experiencing memory impairment. Now a team ... Bochner of Tel Aviv University,s Department of ... same supplement improves the functioning of genes involved ...
(Date:5/21/2013)... scientists have developed many devices that can reopen clogged ... effective, each of these treatments has drawbacks, including the ... MIT analyzes the potential usefulness of a new treatment ... stents, but may pose fewer risks. With this new ... only a brief period, during which it releases a ...
(Date:5/21/2013)... The epigenetic modifications, which alter the way genes ... apparently be detected in the blood of pregnant ... way to foretell depression in the weeks after ... symptoms become debilitating. , The findings of the ... online in the journal Molecular Psychiatry . ...
Breaking Biology News(10 mins):Common food supplement fights degenerative brain disorders 2Evaluating a new way to open clogged arteries 2Evaluating a new way to open clogged arteries 3Genetic predictors of postpartum depression uncovered by Hopkins researchers 2Genetic predictors of postpartum depression uncovered by Hopkins researchers 3
... for tens of thousands of heart patients to have high-tech ... defibrillators, the expensive devices are designed to shock damaged hearts ... which kills 300,000 Americans each year. , But a new ... from their ICDs, a large number won't -- and a ...
... again? It happens, you know. , As we ... our brains--have to "speak" more loudly to get the ... of Delaware researcher Christopher Knight, an assistant professor in ... result of age-related changes in muscle and neurons, elderly ...
... the amount of three particular proteins on their surface increases, ... related receptor proteins, called GPR3, GPR6 and GPR12, on nerve ... researchers increased the amount of the three proteins, the cells ... those on nerve cells with normal levels of the proteins, ...
Cached Biology News:Are one-third of costly implanted heart devices unnecessary? New study suggests yes 2Are one-third of costly implanted heart devices unnecessary? New study suggests yes 3When your brain talks, your muscles don't always listen 2When your brain talks, your muscles don't always listen 3When your brain talks, your muscles don't always listen 43 proteins may play important role in nerve-cell repair 2
Proliferin (C-14)...
... power of your ValveBank system! Program ... a Macintosh computer using graphic 'click-and-drag' timebars. ... print out program listings, then download your ... simple step., EasyCode is used for programming ...
... Jouan MSC series of Class II ... conditions and certification to the world's ... ensures that the cabinets cannot be ... Natural lighting, low noise and arm ...
... The Holten MaxiSafe 2010 Class ... most ergonomical working condition of comfort ... safety, efficiency and performance.,Refined operator, environment ... of both exhausted and recirculated air.,Bottom ...
Biology Products: